|Bid||170.30 x 400|
|Ask||170.34 x 300|
|Day's Range||168.83 - 170.94|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||16.18|
|Dividend & Yield||4.60 (2.75%)|
|1y Target Est||N/A|
Biotech has underperformed the broader market this month, but Jefferies' Michael Yee writes that that's not really a concern--or a surprise. A little more detail about each: AMGN: key incoming questions around scenarios for upcoming REGN injunction appeals decision where buyside consensus is for majority likelihood AMGN wins with some pot'l for court trying to force a financial settlement w/ large royalty (worth $2-3/share). If AMGN loses, there shouldn't be any change to estimates given consensus has not adjusted any 2018+ PCSK9 numbers for a win though AMGN already won the initial federal injunction decision.
The companies will also have a deep focus into specific therapeutic areas
In 2Q17, Amgen’s (AMGN) Enbrel generated revenues of ~$1.5 billion, which represented a ~1% year-over-year decline and a ~24% quarter-over-quarter rise.